Application of naringenin to preparation of drugs for preventing and/or treating aortic dissection

A technology of aortic dissection and naringenin, applied in the application field of medicine, achieving the effects of high yield, simple process, and rich source of raw materials

Inactive Publication Date: 2016-05-25
郑金刚 +2
View PDF1 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no effective drug to control the occurrence and development of aortic dissection

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of naringenin to preparation of drugs for preventing and/or treating aortic dissection
  • Application of naringenin to preparation of drugs for preventing and/or treating aortic dissection
  • Application of naringenin to preparation of drugs for preventing and/or treating aortic dissection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] Example 1. Naringenin gavage inhibits BAPN (β-aminopropionitrile)-induced aortic dissection in juvenile mice

[0031] 1. BAPN-induced aortic dissection in juvenile mice

[0032] Three-week-old male C57 mice were divided into four groups, namely the model control group (BAPN0.8g / kg / d drinking water + normal saline gavage) and the naringenin low-dose group (BAPN0.8g / kg / d Drinking water + naringenin 50mg / kg / d intragastrically), naringenin medium-dose group (BAPN 0.8g / kg / d drinking water+naringenin 100mg / kg / d intragastric administration) and naringenin high-dose group (BAPN0 .8g / kg / d drinking water + naringenin 200mg / kg / d gavage), BAPN was given by gavage while drinking water. During the experiment, the general condition and mortality of the mice were observed. BAPN was taken four weeks after drinking water to observe the incidence of aortic dissection in the mice.

[0033] 2. Naringenin gavage inhibits BAPN-induced aortic dissection in juvenile mice

[0034] The effect of intrag...

Embodiment 2

[0036] Example 2. Naringenin gavage inhibits the occurrence of angiotensin II-induced aortic dissection in aged rats

[0037] 1. Model of angiotensin II-induced aortic dissection in aged mice

[0038] Male C57 mice aged 8-9 months were divided into two groups, respectively given angiotensin II 2500ng / kg / min submerged pump + normal saline (model control group) and given angiotensin II submerged pump 2500ng / kg / min +Gavage with naringenin 200mg / kg / d (naringenin-treated group), start gavage one week before the pump. During the experiment, the general condition and mortality of the mice were observed. The samples were taken 14 days after the pump was buried to observe the incidence of aortic dissection in the mice.

[0039] 2. Naringenin gavage inhibits the occurrence of angiotensin II-induced aortic dissection in aged rats

[0040] The effects of the model control group and the naringenin treatment group on the incidence of aortic dissection in aged C57 mice induced by angiotensin II are...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides application of naringenin to the preparation of products for preventing and / or treating aortic dissection. The drugs for preventing and / or treating aortic dissection are safe and low-toxic, and high in pharmacological action; the source of raw materials are rich and wide, the price is low, and the raw materials can be obtained from crude products or monomer of naringin through a hydrolysis method, obtained by extracting from medicinal materials containing naringenin, or obtained by synthesis through other chemical methods; the cost is low, the process is simple, and the yield is high; curative effect is definite, and the effective dose is low. The application provides a novel source of drugs for preventing, diagnosing, detecting, protecting, treating and researching aortic dissection diseases, is easy to promote and apply, and can produce huge social benefit and economic benefit within a short time.

Description

Technical field [0001] The invention relates to a new drug use of naringenin, in particular to the application of naringenin in the preparation of drugs for preventing and / or treating aortic dissection. Background technique [0002] Aortic dissection is one of the high-risk diseases in the cardiovascular field. It refers to the tear of the aortic intima, and the circulating blood enters the aortic wall through the breach, resulting in the stratification of the vascular wall. The torn blood vessel wall is very weak and easy to expand or rupture, and the latter is often fatal. Clinically, about 36%-50% of patients with untreated aortic dissection die within 48 hours after the onset of illness, about 65%-75% die within 2 weeks, and the 1-year mortality rate is as high as 90%, and the 10-year mortality rate is almost 100% (Huang Dong, Liu Mingya, The occurrence mechanism and diagnosis and treatment strategies of aortic dissection, Advances in Cardiovascular Diseases, 2007,28(4):631-...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P9/00
CPCA61K31/352
Inventor 郑金刚孔炜高艳香于长安
Owner 郑金刚
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products